Tuesday 16 June 2026

The Pharmaletter

Aliada Therapeutics

A USA-based neuroscience-focused company working towards overcoming the delivery hurdle in large molecule drug development.

Company Overview

Want to Update your Company's Profile?


Latest Aliada Therapeutics News

Chiesi licenses AbbVie subsidiary's BBB platform
13 November 2025
The week in pharma: action, reaction and insight – week to November 1
3 November 2024
AbbVie punts $1.4 billion to buy early-stage Alzheimer’s drug developer Aliada
29 October 2024
Chiesi Global Rare Diseases enters co-development deal with Aliada
16 August 2023
More Aliada Therapeutics news >


Today's issue

Protillion and Merck & Co sign AI drug discovery pact
Biotechnology
Protillion and Merck & Co sign AI drug discovery pact
16 June 2026
Biotechnology
Moderna prepares for multiple product launches
16 June 2026
Generics
Cancer drug shortage in India: platinum prices push chemo to the brink
16 June 2026
Biotechnology
Soleno Therapeutics presents new Vykat XR data at ENDO
16 June 2026
Pharmaceutical
Takeda’s oveporexton shows broader benefits in Phase III narcolepsy studies
16 June 2026
Biotechnology
Lonza licenses dual-payload ADC technology to Antharis for GI cancer programs
16 June 2026
Biotechnology
Dimerix out-licenses DMX-200 to Everest for Asian markets
16 June 2026




Copyright © The Pharma Letter 2026

 |  Headless Content Management with Blaze